Trian Fund Management, an activist investment firm, has published an open letter and slide deck addressed to the board of Solventum Corporation, urging the company to take steps to create greater shareholder value. The letter, dated April 30, 2026, criticizes Solventum's recent financial performance and strategic direction.
Solventum, a healthcare spinoff from 3M, has seen its stock price decline since its separation in April 2024. Trian, which holds a significant stake in the company, argues that the board has failed to address operational inefficiencies and capital allocation issues. The firm is calling for a strategic review, including potential asset sales or a merger.
In the open letter, Trian highlights that Solventum's market capitalization has dropped by over 30% since the spinoff, underperforming peers in the healthcare sector. The investment firm proposes specific measures, such as cost-cutting initiatives and a focus on core businesses, to unlock value for shareholders.
Solventum's board has not yet publicly responded to Trian's letter. The company's shares rose 2.5% in pre-market trading following the news, indicating investor interest in the activist campaign.
